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1. Introduction
The nervous system consists of the peripheral nervous system (PNS) and the central nervous
system (CNS). Most functions of the nervous system are performed by neurons, such as
movement and sense. But neurons lose the proliferation ability after maturation. Under
pathological conditions, injured neurons will degenerate and die. Eventually, patients will lose
some of the normal functions [1]. Although astrocytes are required for neurogenesis, synaptic
maturation and neuronal activity maintenance, in current opinions, neurological diseases are
caused by neurodegeneration or neuronal cell death. How to stimulate the neuroregeneration
is still a key challenge in both fundamental and clinical research. Thus far, scientists have made
a lot of efforts to develop drugs and devices to stimulate the functional recovery after nerve
injury. There are no efficient methods available to stop or reverse neurodegeneration or
neuronal cell death [2].
Current strategy for peripheral nerve injuries when the gap is less than 5 mm is to join the
distal and proximal stumps of the damaged nerves by microsurgery. When the gap is longer
than 5 mm, direct microsurgery will cause the tension of nerve fibers. A nerve graft needs to
be used to fill the gap and make the connections between the distal and proximal stumps of
the damaged nerves, in order to facilitate the regenerated nerve fibers to find their targets
easily during the recovery [3, 4]. Autogenous nerve grafts require a second surgery to isolate
the donor nerve tissue, which often leads to second deformities and the morbidities of donor
tissues. On the other hand, the quantity for nerve autografting is quite limited. Although
allografts and xenografts could serve as a possible alternatives to autografts, systemic immuno-
rejection remains a major concern. Immunosuppression drugs were used to inhibit systemic
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
immuno-rejection, which will cause adverse side effects [5, 6]. Recent advances in stem cell
biology and biomaterials make it possible to develop biodegradable nerve grafts for neural
tissue engineering, nerve repair and regeneration. Here, we focus on stem cell-derived neural
cells and biodegradable 3D neural scaffolds or conduits for nerve regeneration.
2. Support cells derived from stem cells for nerve repair
For peripheral nerve repair, axon outgrowth needs aligned Schwann cells (called astrocytes in
central nervous system) to guide the orientation and to give the support. On the other hand,
damaged neurons need to be replaced to perform appropriate functions. Recent progress in
stem cell biology and techniques allows us to generate large quantities of functional neurons
and transplantable astrocytes from stem cells [7, 8]. Stem cell-derived neural cells have been
used for the studies of axon regeneration and for the treatment of neurological diseases, such
as spinal cord injury (SCI), Parkinson’s disease (PD), Alzheimer’s disease (AD) and amyotro‐
phic lateral sclerosis (ALS), and showed promising functional recovery in the animal models
of these neurological diseases [9-12]. Transplanted stem cell-derived neurons could integrate
and form functional synaptic connections with host neurons [13]. Furthermore, transplanted
stem cell-derived immature astroglial cells could become mature astrocytes by forming
connections with blood vessels and transplanted induced oligodendrocyte progenitor cells
(iOPCs) could form myelin sheath [14, 15].
2.1. Schwann cells
In the PNS, the majority of glial cells are Schwann cells including myelinating Schwann cells
and non-myelinating Schwann cells, which play essential roles for supporting normal neuronal
functions and the survival and axonal regeneration of neurons after nerve injury. The myeli‐
nating Schwann cells forming myelin sheaths around axons insulate individual axon. Similar
functions are performed by in the CNS oligodendrocytes. The non-myelinating cells in the PNS
show similar functions with astrocytes in the CNS, which mediate the development, mechan‐
ical and metabolic support functions and promoting neuronal survival after injury. Schwann
cells are involved in maintaining normal functions of PNS, including secretion and nerve
extracellular matrix, nerve development and maturation, and modulation of neuromuscular
junction transmission [16]. Schwann cells also produce and secret different neurotrophic
factors, such as nerve growth factor (NGF), brain derived neurotrophic factor (BDNF),
neurotrophic factor-3 (NT-3), glial derived neurotrophic factor (GDNF) and insulin-like
growth factor (IGF) [17, 18]. All these neurotrophic factors are indispensable for neural
development and regeneration. Furthermore, Schwann cells present antigens to T-lympho‐
cytes and are involved in the clearing of myelin debris by phagocytosis.
In response to nerve injury,  Schwann cells  undergo proliferation and their  basal  lamina
forming nerve conduit to support and guide axon regeneration and outgrowth. The DNA
and RNA biosynthesis and up-regulation of Schwann cells could be observed as early as 2
h  after  injury.  In  1980,  Salzer  and  Bunge  have  found  that  direct  mechanical  injury  is
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mitogenic  for  Schwann  cells  during  Wallerian  degeneration  and  Schwann  cells  indeed
proliferation in situ after excision [19]. However, the proliferative ability of Schwann cells
is  low in vivo.  In  most  cases,  endogenous Schwann cells  proliferation is  not  enough to
support  and  guide  axon  regeneration  and  outgrowth.  Extra  Schwann  cells  need  to  be
transplanted after nerve damage. Morrissey et al. developed a culture method that could
yield  up  to  98%  pure  Schwann  cells  from  adult  rat  sciatic  nerve  [20].  Imaizumi  et  al.
transplanted Schwann cells to the rat model of SCI and characterized the functional recovery
by  electrophysiological  recording.  They  found  that  Schwann  cells  transplantation  could
form new pathway across the transaction site and provide a functional recovery of SCI [21].
Guenard  et  al.  isoloated  and cultured  Schwann cells  from rat  sciatic  nerve  and seeded
cultured Schwann cells into semipermeable guidance channels. And then, they implanted
Schwann cells-loaded nerve guidance channels into 8 mm rat sciatic nerve gap. Interesting‐
ly, they found that there was a positive correlation between the number of transplanted
cells and the number of myelinated axons. Furthermore, they found that implanted Schwann
cells loaded nerve guidance channels could improve the neural regenerative process [22].
Berrocal et al. implanted absorbable collagen conduits in combination with autologous SCs
to a critical size defect (13 mm) in the sciatic nerve of male Fischer rats. Their results showed
that  absorbable  collagen conduits  loaded with  Schwann cells  significantly  enhanced the
regeneration of myelinated axons. The generated axons could grow into the nerve stump
into the proximal and middle of the tube 4 weeks after implantation. The regeneration of
myelinated axons occupied the entire length of the nerve guide 16 weeks after implanta‐
tion. Functional recovery was observed in the animals who received implant treatment [23].
However, transplantation of Schwann cells is impractical for clinical application. Firstly, nerve
tissue that could be used to isolate Schwann cells is limited in the patients. Secondly, Schwann
cells need time to grow adequate amounts of cells for transplantation. It will take a couple of
weeks, even longer. Thirdly, delayed Schwann cells transplantation often reduces the func‐
tional recovery after nerve injury compared with whose received acute application. Scientists
began to seek other alternative sources for the treatment after nerve injury. Schwann cells can
be generated from adult stem cells, such as mesenchymal stem cells (MSCs) and neural stem/
progenitor cells (NSPCs), and pluripotent stem cells including embryonic stem cells (ESCs)
and induced pluripotent stem cells (iPSCs) in vitro and in vivo. Stem cells are good alternative
source for Schwann cells. Furthermore, stem cells could locally differentiate into glial cells as
well as neurons after transplantation.
2.2. Mesenchymal stem cells
Mesenchymal stem cells (MSCs) can almost be found in any adult organ and can be easily
harvested from patients. MSCs are capable of self-replication to many passages and can be
expanded to enough cell numbers for tissue and organ regeneration. Although MSCs have
been firstly harvested from the bone marrow, they actually have different properties from
bone marrow stromal cells (BMSCs).  BMSCs are a highly heterogeneous cell  population,
which includes multiple cell types with different potentials for proliferation and differentia‐
tion. On the contrary, bone marrow MSCs are a more homogenous subtype of mononu‐
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clear  progenitor  cells  that  have  stem  cell  properties,  such  as  self-renewal  capacity  and
multipotency  [24,  25].  Bone  marrow  MSCs  undergo  to  differentiate  into  adipocytes,
chondrocytes and osteocytes in culture. In addition, bone marrow MSCs express specific
cell surface markers, such as positive for CD105, CD166, CD29 and CD44 and negative for
CD14, CD34 and CD45. MSCs can also be derived from other non-marrow tissues, such as
the liver and adipose, lung, peripheral blood, as well as amniotic fluid, umbilical cord blood
and Wharton’s jelly of the umbilical cord [26, 27]. MSCs are not only able to differentiate
into mesodermal cell  phenotypes but also into ectodermal lineage,  Schwann cells,  astro‐
glial cells, oligodendrocytes and neurons, such as dopaminergic and purkinje neurons and
have been used to treat cardiac and neurological disorders [28, 29]. Adipose derived stem
cells (ADSCs) are a subtype of MSCs, which isolated from adipose tissue. Like bone marrow
MSC, ADSCs are also self-renewal capacity and ability to differentiate into multiple lineages.
Compared bone marrow MSC, people found that ADSCs are easier to harvest and culture
for longer periods and grow faster [30]. MSCs could be induced to differentiate into neurons
and Schwann cells in the regular culture vessels. Furthermore, MSCs have been induced to
differentiate  into  neuronal-like  cells  expressing  neuronal  biomarkers,  such  as  Tuj1  and
neurofilament, and neural progenitor cells forming neurosphere-like structure in the three
dimensional  (3D)  biodegradable  scaffolds  [24,  31-33].  All-trans  retinoic  acid  is  a  most
common  drug  used  to  initiate  Schwann  cell  differentiation  of  MSCs.  Forskolin,  FGF2,
Platelet-Derived Growth Factor (PDGF) and Neuregulin NRG1-1 are often used to force the
final  Schwann  cell  differentiation  [34].  Interestingly,  human  MSCs  can  also  be  induced
differentiated into Schwann cells. Human MSCs-derived Schwann cells have Schwann cell
morphology and expression Schwann cell-specific proteins, such as p75 neurotrophin factor.
Furthermore, Human MSCs-derived Schwann cells secrete several growth factors, such as
hepatocyte growth factor  (HGF) and vascular  endothelial  growth factor  (VEGF) in vitro
and  in  vivo.  Transplantation  of  human  MSCs-derived  Schwann  cells  dramatically  en‐
hanced axonal outgrowth in an animal model of spinal cord injury [35].
Although a couple of reports showed that that MSCs can be used to generate neuronal cells,
this phenomenon was recently called into question [36, 37]. Firstly, there is no evidence that
neural tissues directly generated from MSCs. Secondly, the functional properties of MSCs-
derived neurons have not been extensively studied, such as patch clamp recording for
neuronal activities and high-performance liquid chromatography (HPLC) for neurotransmit‐
ter release. Thirdly, similar culture conditions used to induce MSCs to differentiate into
neurons could also induced fibroblasts to neuronal-like cells. However, there is no doubt about
clinical improvements demonstrated in animal models and patients after treatment with
MSCs. People believe that these clinical improvements are from growth factors and cytokines
released from MSCs. MSCs-derived growth factors and cytokines could promote neurogenesis
and angiogenesis of damaged brain tissue and inhibit the process of apoptosis. Transplantation
of MSCs has shown a significant functional recovery of the animal model of stroke. Never‐
theless, MSCs are a good source for cell therapy.
Peripheral Neuropathy28
2.3. Neural stem/progenitor cells
Previous studies showed that adult neural stem/progenitor cells (NSPCs) not only locate in
neurogenic regions, the subventricular zone (SVZ) and the subgranular zone (SGZ) of the
hippocampal dentate gyrus, but also locate in some non-neurogenic regions, such as cerebral
cortex, cerebellum and spinal cord [7]. Multipotent CNS stem-like cells were first cultured from
the adult striatum by neurosphere assay. The neurosphere culture system has been widely
used to isolate and expand NSPCs under serum-free media conditions as well as with the
presence of epidermal growth factor (EGF) and fibroblast growth factor-2 (FGF2). NSPCs are
self-renewing, multipotent progenitors in the nervous system that could be induced to
differentiate into the three phenotypes in the nervous system under appropriate condition,
such as neurons, astrocytes and oligodendrocytes. Functional properties of NSPCs-derived
neurons have been characterized by immunostaining and clamp patch recording. NSPCs-
derived neurons have all the properties of native neurons. NSPCs have been widely used for
the studies of neural development and regeneration. After transplantation, NSPCs-derived
neurons could replace the dead neurons in the animal’s model of neurological disorders, such
as AD, PD and SCI and have shown the functional recovery in these animals’ models [38, 39].
In our previous studies, we isolated and cultured NSPCs from mouse and rat brains under
DMEM/F-12 medium supplement with B27 (2%) or N2 (1%), EGF (10 ng/ml) and FGF2 (10 ng/
ml) by neurospheres assay. After 2-3 passages, most of neurospheres are positive to Nestin, a
neural stem cell marker. We found that BrdU could be detected 16-18 h after NSPCs were
cultured in the presence of BrdU. 5-bromo-2'-deoxyuridine (BrdU) is a synthetic nucleoside
that is an analog of thymidine and is widely used in the detection of proliferating cells in vitro
and in vivo. When NSPCs were cultured in the serum containing medium, they are easily
induced to differentiate into neurons and astrocytes. These results demonstrate that NSPCs
from mouse and rat brain have a high proliferative ability and multipotency. After transplan‐
tation to AD rats with fimbria-fornix transection, NSPCs could migrate into adjacent brain
tissue and locally differentiate into neurons and astrocytes. Y-maze testing showed that
transplanted NSPCs could improve the learning and memory in the rat model of AD [13,
40-45]. NSPCs have been cultured in a 3D bioactive scaffold derived from porcine urinary
bladder matrix (UBM) for the treatment of traumatic brain injury (TBI). UBM was able to
support extended proliferation and differentiation of NSPCs. After transplantation into rat TBI
model, the transplants could reduce neuronal loss and white matter injury, and also signifi‐
cantly ameliorate motor, cognitive and memory impairments [46]. Furthermore, NSPCs-
loaded PLGA scaffolds have been used for the treatment of animal model of SCI. NSPCs could
differentiate into neurons and glial cells in the PLGA scaffolds after transplantation and make
functional synaptic connections with proximal and distal nerve stumps. Retrograde tracking
studies showed that the tracer could pass through the nerve gap and be found in the brain [47].
In the developing CNS, the initial symmetric cell division of NSPCs occurs to produce more
identical stem cells and form neural tube. As development progresses, symmetric cell division
is gradually replaced by asymmetric cell division which produce one stem cell and one neural
precursor cell. Previous studies have identified neuronal restricted precursors (NRPs) and glial
restricted precursors (GRPs) in the brain and spinal cord. These cells are more limited in their
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differentiation potential than NSPCs. NRPs have the tendency to differentiate into neurons
and GRPs have the tendency to differentiate into glial cells. After transplantation in the model
of SCI, transplanted GPCs demonstrated to differentiate into oligodendrocytes and form
myelin around axons and increase the locomotor recovery [48]. Furthermore, NSPCs have been
used along with Schwann cells to improve axonal regeneration. Olson et al. transplanted
NSPCs and Schwann cell-loaded PLGA polymer scaffold into transected spinal cord. They
found that NSPCs could differentiate into neuronal cells in the scaffold channels and NSPCs
and Schwann cell-loaded PLGA polymer scaffold could facilitate axonal regeneration across
the transected spinal cord [49].
The major drawback of NSPCs is that NSPCs locate in the deep of brain and spinal cord. It is
almost impossible to harvest autologous NSPCs for nerve repair in clinic. Although NSPCs
could be obtained from aborted embryos, ethical issue plagues their clinical application.
2.4. Induced neural cells
In 2012, John B. Gurdon and Shinya Yamanaka shared the Nobel Prize in Physiology or
Medicine for their discovery that mature cells can be reprogrammed to become pluripotent.
In 1962, Gurdon showed that adult frogs could be generated from the nuclei of single somatic
cells by nuclear transfer. In 2006, Yamanaka’s group showed that somatic fibroblasts could be
induced to ESC-like cells, called iPSCs, by four transcription factors including Oct4, Sox2, Klf4
and c-Myc. These iPSCs have the ability to generate all three lineages, endodermal, mesoder‐
mal and ectodermal cells [50]. Later, several groups using similar strategy successfully
generated iPSCs from patients. Patient-derived iPSCs have been used to study the pathological
mechanisms and drug testing [51, 52]. The principle of differentiated cells regaining pluripo‐
tency and conversion of one cell type into another not only let us re-think about the funda‐
mental principles of development but also allow us re-consider autologous cell replacement
therapy. Induced PSCs have been used for peripheral nerve repair. Uemura et al. transplanted
iPSCs-derived neurospheres-seeded sponge polymer composed of 50% PLA and 50% PCL to
5 mm sciatic nerve gap. The recovery of motor and sensory function can be observed as early
4 weeks. Twelve weeks after transplantation, histological evaluation showed that iPSCs
differentiated into GFAP-and S100-positive Schwann cells and Tuj1-and neurofilament-
neuronal cells [53]. Wang et al. transplanted iPSCs-derived neural crest stem cells (NCSCs)-
loaded electrospinning nanofibrous nerve conduits composed of 70% PLA and 30% PCL to 6
mm sciatic nerve gap. Transplanted NCSCs were able to promote regeneration of peripheral
nerves. But they did not observed neuronal differentiation of NCSCs [54].
In 2010, Dr. Wernig’s group used a cocktail of transcription factors, Ascl1, Brn2 and Myt1l,
successfully convert fibroblasts into functional neurons, named induced neurons [55].
Interestingly, induced neurons have been generated from fibroblasts of patients [56]. Further‐
more, induced dopaminergic neurons could integrate into host brain after transplantation.
Recently, several group used similar techniques to successfully generate induced NSPCs [57,
58]. Induced NSPCs have similar properties with NSPCs isolated from brain tissue. More
interestingly, two groups generated iOPCs from somatic fibroblasts. After transplantation,
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iOPCs could differentiate into oligodendrocytes and form myelin sheath. So far, there are no
reports showed that iOPCs have been used to treat peripheral nerve injury [14, 15].
3. Biodegradable polymers as nerve guidance conduits for nerve repair and
regeneration
The current gold standard for peripheral nerve repair is nerve autografting. However, this
approach is associated with a number of clinical complications, in particular, donor site
morbidity, limited availability, and nerve site mismatch and neuroma formation at the donor
site [59]. Artificial nerve guidance conduits have been developed for bridging the gap. This
strategy has been widely accepted for basic research and clinical applications. In general, a
nerve guidance conduit for reconnecting the two nerve stumps (i.e., the proximal and distal
nerve stumps) contains an appropriate substrate with longitudinal orientation guidance to
direct axons to find their targets. To date, the majority of nerve guidance conduits developed
is composed of biodegradable polymers. A few of them are FDA-approved and commercially
available. These nerve conduits have achieved considerable success in treatment of gap defects
with the distances up to 20-25 mm. To further improve on the regeneration capacity of nerve
conduits, a number of strategies have been actively pursued, in particular, the combination of
nerve conduits with stem cell technologies [60]. In this review, we discuss the key design
parameters of nerve conduits, including materials, fabrications methods, and incorporation of
bioactive molecules, which play critical roles in governing the cellular fate of the stem cells
cultivated in the nerve guidance conduits. Through analyzing and summarizing these
experimental results, our goal is to provide insights into the future design of nerve conduits
with much improved therapeutic efficacy.
3.1. Materials consideration for use in nerve guidance conduits
Materials selection is critical to the performance of fabricated nerve guidance conduits. Ideally,
materials to be employed for nerve repair need to fulfill the following requirements.
1. They must be biocompatibility for supporting cell growth, differentiation and function.
2. They must be able to provide appropriate surface and mechanical properties that mimic
nerve tissue.
3. They must be immunologically inert.
4. They must be biodegradable or bio-absorbable.
5. They must be able to be sterilized.
6. They must be readily fabricated into the desired configurations of conduits.
7. Their production must be amenable to industrial scale-up.
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3.2. Materials used in nerve guidance conduits
In the past decades, a broad range of materials have been explored for preparation of nerve
guidance conduits for peripheral nerve repair. They can be broadly divided into two catego‐
ries: naturally-derived biopolymers and synthetic polymers. As can be seen from the following
discussion, these materials can address the aforementioned materials considerations to various
degrees.
Table 1. Examples of naturally-derived and synthetic polymers used in nerve guidance conduits.
Naturally-derived biopolymers. Examples of the naturally-derived biopolymers for nerve
guidance conduits include type I collagen, fibronectin, fibrin glue, gelatin, hyaluronic acid,
alginate, chitosan, agarose and silk fibroin etc. These materials are typically hydrophilic, and
form hydrogel-based matrices by either physical or chemical crosslinking. It is also worth
noting two types of multicomponent matrices, such as MatrigelTM and decellularized nerve
allografts or xenografts. MatrigelTM is a commercial extracellular matrix (ECM) extract from
tissue cultured mouse sarcoma cell lines. It gels in situ at room temperature. MatrigelTM
contains laminin, heparin sulphate, type IV collagen, entactin, nidogen and growth factors.
Decellularized nerve allografts or xenografts are matrices that preserve the inherent structural
characteristics of nerve. For instance, Avance® Nerve Graft is a commercially available
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decellularized allograft processed from human peripheral nerve tissue, which has been used
clinically for reconstruction of periphery nerve gaps with positive results [61].
Naturally-derived biopolymers have demonstrated a number of advantages in the applica‐
tions of nerve repair. They are in general biocompatible, and biodegradable or bioresorbable.
They form hydrogels with structural and mechanical properties similar to nerve tissue. In
addition, some of the biopolymers contain cell adhesion moieties, such as type I collagen and
fibronectin, which encourages neuronal attachment and outgrowth. However, immunogenic‐
ity as a result of animal resources remains a major concern over their practical applications. In
the case of MatrigelTM, its origin in mouse sarcoma cells plagues its use in clinical applications.
Naturally-derived polymers are also known for batch-to-batch variations, and lack of flexibil‐
ity in terms of structural engineering to modulate the physiochemical properties and degra‐
dation kinetics of materials.
Synthetic polymers. Compared to naturally-derived biopolymers, synthetic polymers offer
greater flexibility in modulating the physical properties of materials through engineering the
polymer composition such as (co)monomer structure and side chain chemistry, and polymer
molecular weight. They are also much more amenable to various technologies for materials
fabrication. On the other hand, it is noted that the majority of synthetic polymers used in nerve
repair lack biocompatibility and bioactivity, which limits cell attachment, growth and differ‐
entiation. Viable approaches to overcome the limit involve compositing synthetic polymers
with bioactive molecules, and surface functionalization of nerve conduits with bioactive
molecules. These approaches will be discussed in detail in Section 3.3.
At the early stage of nerve guide development, several non-biodegradable polymers have been
explored to produce nerve guides, including, for example, silicone rubber, polyvinyl alcohol
(PVA), polyethylene glycol (PEG), polyN-2-hydroxypropyl-methacrylamide (pHPMA) and
poly2-hydroxyethyl methacrylate (pHEMA). A major disadvantage of non-biodegradable
nerve conduits is that a second surgery is required to remove the conduits as their chronic
presence impede nerves remodeling. In addition, studies have shown that the chronic presence
of non-biodegradable conduits led to the inflammatory reactions and scar tissue formation,
which ultimately inhibit functional nerve recovery [62, 63].
Amongst the synthetic polymers explored for nerve guidance conduits, a range of biodegrad‐
able aliphatic polyesters have attracted most attention. These include, for example, poly(gly‐
colic acid) (PGA), polylactide (PLA), poly(lactic-co-glycolic acid) (PLGA), poly-ε-caprolactone
(PCL) and poly-3-hydroxybutyrate (PHB) etc. These material typically produce relatively rigid
scaffolds with hydrophobic surface. Their degradation is predominantly medicated by
hydrolysis of their ester linkages in physiological conditions. The degradation rate is depend‐
ent on the polymer structure, molecular weight, or its crystallinity. For instance, among PGA,
PLA and PCL of similar molecular weights, the degradation rate is PGA > PLA > PCL, as a
result of increased hydrophobicity [64]. This provides a basis for tailoring the polymer
degradation kinetics by varying the structure and ratio of the monomers used for polymeri‐
zation. A good example is PLGA, whose degradation rate depends on the ratio of lactide to
glycolide used for the polymerization, i.e., higher content of glycolide units leads to faster
degradation rate, with an exception of 50:50 monomers' ratio that gives rise to the fastest
Neural Differentiation of Stem Cells in Biodegradable Three-Dimensional Scaffolds – A Novel Strategy…
http://dx.doi.org/10.5772/58559
33
degradation rate [65]. Synthetic biodegradable polymers have been widely used to fabricate
different kinds of films or scaffolds to support cell growth in vitro and in vivo.
Figure 1. Immunocytochemistry assay showed proliferation of embryonic stem cells in 3D cellulosic hydrogel scaffolds
after 2 days plating. A. Oct4 showed the pluripotency of embryonic stem cells. B. The total cells were showed by DAPI.
C. A merges with B. D. DIC imaging showed proliferation of embryonic stem cells in 3D hydrogel scaffolds.
Despite the substantial research activities in engineering of polymer biodegradability,
development of neural matrices with desired degradation kinetics in the course of nerve
regeneration still remains a key challenge. This is due to the inherent complexity of in vivo-
degradation, which necessitates multidisciplinary efforts to bring together materials scientists,
biologists and clinicians to tackle this challenge. Ideally, a nerve conduit should provide
adequate mechanical support and protection to facilitate axonal regeneration across the nerve
gap, while undergoing degradation with the kinetics matching the rate of nerve regeneration,
in order to make way for the regenerating nerve. Development of appropriate in vitro-models
that can simulate in vivo degradation of nerve conduits may help to speed up the problem-
solving process and facilitate the delivery of nerve conduits with desired in vivo-degradation
profiles to meet specific needs in clinical applications.
3.3. Key considerations in nerve conduit design
In its simplest form, a nerve conduit takes the form of a hollow tube for bridging nerve gap
defects. A nerve conduit implant needs to satisfy a set of basic requirements in both material
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and technical aspects, including biocompatibility, non-immunogenicity, biodegradability/
bioabsorbability, mechanical integrity with nerve tissue, and ease of sterilization and fabrica‐
tion into the desired dimensions. These considerations underpin the development of a variety
of single lumen hollow conduits that have shown positive effects in treatment of short defects
(< 20-25 mm). These conduits differed mostly in the structure and composition of the polymers
used for conduit fabrication. Some of them have already gained approval in clinical applica‐
tions, which will be discussed in detail in Section 3.4.
To improve the therapeutic efficacy in treatment of large nerve defects, a number of biomimetic
strategies have recently been adopted to modify the existing design of nerve conduits, by
providing bio-regulative cues to better mimic nerve tissue at various levels (anatomic, physical
or structural). The ongoing research activities in this area have been catalyzed by our increasing
understanding of in vivo-behavior of nerve conduits, as well as the advances in material
fabrication and in tissue engineering. Some of the key strategies will be briefly reviewed here.
Topographic guidance. Longitudinally-oriented topographic cues have been introduced to
nerve conduit design, with a view to promoting the growth and orientation of regenerating
axons. This can be microfibers, multichannels, or 3D matrix fillers with longitudinally-oriented
architectures, as is illustrated in Figure 2. For instance, Kim et al reported on polysulfone
conduits containing uniaxially electrospun nanofibers of poly(acrylonitrile-co-methylacrylate)
[66]. Incorporation of such aligned sub-micron topographic cues was shown to significantly
promote both sensory and motor nerve regeneration across a 17 mm peripheral nerve gap in
a rodent model, without the delivery of any exogenous neuro-simulative agents (e.g., neuro‐
trophic factors and extracellular matrix proteins). Nerve conduits with aligned multichannels
can be prepared using an injection-molding technique, the same technique as used for
fabrication of single lumen nerve conduits.
ECM proteins, such as laminin, fibronectin, and collagen, are good candidates of intraluminal
fillers for nerve conduits as they promote axonal extension. Technologies are required in order
to produce aligned intraluminal structures of these proteins. An early study by Dubey et al
employed magnetic fields to align the collagen gels in Teflon tubes, which gave rise to
enhanced neurite elongation from dorsal root ganglia explants [67]. Matsumoto et al developed
nerve conduits of PGA that were further coated with collagen and internally filled with
longitudinally-oriented, laminin-coated collagen microfibers [68]. Axonal regeneration over
an 80 mm gap of canine peroneal nerves was demonstrated. Alternatively, using a special
freezing process, 3D matrixes collagen with longitudinally oriented pores can be prepared,
which may find applications as aligned intraluminal fillers [69].
Mechanical compliance. Mechanical compliance of nerve conduits is an important consider‐
ation in conduit design. It plays a key role in directing cellular and tissue response to implanted
nerve conduits, which could affect the performance of the nerve conduits. In addition, studies
have shown a critical role of material mechanical properties in directing stem cell differentia‐
tion [70, 71]. Nerve tissues are soft and highly hydrated, while nerve conduits prepared from
synthetic polymers, such as polyesters, are often rigid and hydrophobic. Strategies have been
sought to develop hydride conduits that integrate synthetic polymer with naturally-derived
biopolymers into various configurations to unify the advantages of both types of materials.
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Examples of hydride conduits are those made of composites of naturally-derived biopolymers
and synthetic polymers, or those incorporated with a soft hydrogels of ECM proteins to
provide the matrix for axonal growth and regeneration [72, 73]. As previously discussed, those
ECM hydrogel filaments need to be aligned to enable optimal nerve regeneration.
Surface bioengineering. This strategy involves coating or surface modification of nerve
conduits with neurostimulatory molecules, in particular cell adhesion molecules, to promote
cell adhesion, proliferation and differentiation, thereby improving the regeneration capacity
of nerve conduits. The cell adhesion motifs that have been explored for nerve conduits include
collagen, laminin, lamnin fragment peptides, fibronectin and Arg-Gly-Asp (RGD). For
instance, laminin has often been used for coating of nerve conduits, and has been shown to
enhance Schwann proliferation and migration, and neurite outgrowth. RGD-modified PCL
nanofibers using a polyether diisocynate was shown to promote faster Schwann cell migration
and axonal growth [74].
Growth factor delivery. As discussed previously, neutrotrophic factors play a critical role
in  promoting  neuronal  survival  and  differentiation.  The  capability  to  in  situ  deliver
neurotrohic  factors  is  now  becoming  an  essential  feature  of  next  generation  of  nerve
conduits. A popular approach is embedding growth factors in a hydrogel matrix that serves
as intraluminal filler. Release of the entrapped growth factors can be diffusion-controlled
and/or degradation-controlled, which is subject to the nature of the matrix-growth factor
interactions. Increasing the crosslinking density of the hydrogel matrix can produce stiffer
matrix, which may lead to more retarded release of the entrapped growth factor. Howev‐
A
B
C
Figure 2. Schematic illustration of the nerve conduits modified with longitudinally oriented topographic cues. (S)
nerve conduit with aligned nanofibres or microfibers; (B) nerve conduit containing multichannels; (C) nerve conduit
containing 3D scaffolds with longitudinally oriented pores.
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er, this approach may have limitations as the level of stiffness of a hydrogel matrix should
not pose any hindrances to the axonal growth across the lumen. Inclusion of heparin as a
component of hydrogel matrix has shown a viable approach to modulate heparin-binding
growth factors delivery. For instance, a heparin-containing hydrogel matrix was reported,
comprising of fibrin with a high excess of immobilized heparin-binding peptides, heparin
and neurotrophins, such as beta-nerve growth factor (β-NGF), brain-derived neurotrophic
factor  (BDNF) and neurotrophin-3  (NT-3)  [75].  The heparin bound to  both the  immobi‐
lized peptides, and neurotrophins, which was responsible for slow diffusion release of β-
NGF,  BDNF  or  NT-3.  Enhanced  neurite  extension  was  demonstrated  in  these  heparin-
containing matrices, but not in the matrices containing only fibrin and neurotrophins. A
recent study also showed that the heparin-containing fibrin matrices with NGF resulted in
a high level of sciatic nerve regeneration as compared to the control groups [76].
Alternatively, growth factors can be introduced into nerve conduits either as a component of
coating or being embedded directly in the wall. For example, NGF-containing microspheres
of PLGA were formulated with an aqueous solution of poly(2-hydroxyethyl methacrylate),
and coated on the inside of pre-formed nerve conduits prepared from poly(2-hydroxyethyl
methacrylate-co-methyl methacrylate) [77]. The microsphere-coated nerve conduits showed
more sustained release of NGF for > 28 days, compared to those coated with poly(2-hydrox‐
yethyl methacrylate) and NGF, though no in vivo studies were reported. Nerve conduits with
the capacity of co-delivery of synergistically acting glial cell-line derived neurotrophic factors
(GDNF) and NGF were reported by Madduri et al [78-80]. GDNF and NGF were loaded into
the nerve conduits of collagen, and dried and coated with PLGA in ethyl acetate. In vitro studies
showed that the combination of GDNF and NGF exerted a synergistic effect on the axonal
elongation, axonal branching and growth kinetics. Compared to the conduits releasing GDNF
alone, enhanced early nerve regeneration in a 10 mm rat sciatic nerve gap model was also
demonstrated for the conduits with co-delivery of GDNF and NGF.
3.4. Commercially available nerve guidance conduits
Table 2 summarizes the nerve guidance conduits that have been approved by the US Food and
Drug Administration (FDA), and/or the European Union with a Conformité Européenne
certification (CE) for clinical applications. They are all in the configuration of single-lumen
tube. NeuraGen™, NeuroMatrix™ and NeuroFlex™ are derived from type I collagen, which
is a major component of ECM. AxoGuardTM is made of ECM materials derived from porcine
small intestine. It contains almost intact ECM, including cell adhesion proteins, growth factors,
glycosaminoglycans and proteoglycans etc. SaluBridgeTM and SaluTunnelTM are non-resorba‐
ble conduits, and are prepared from PVA hydrogel. Neurotube® is a PGA-based, woven
tubular device, with high porosity to provide an oxygen-rich environment for the regenerating
nerve [60]. Neurolac® is the only FDA approved transparent conduit based on synthetic
biodegradable polyesters. It is noted that the fabrication of these nerve guides do not involve
any biofunctionalization with or incorporation of bioactive molecules. These nerve conduits
thus meet only the basic requirement of conduits, by providing physical guidance cues via
conduit morphology to direct axonal regeneration.
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Product name Materials Degradation Some key issues
SaluBridgeTM, SaluTunnelTM
(from SaluMedica) PVA Non-resorbable Non-resorbability
NeuroflexTM, NeuroMatrixTM
(from Collagen Matrix Inc.) Type I bovine collagen 4-8 months
Risk of adverse immune
response
NeuraGen®
(from Integra life Science) Type I bovine collagen 36-48 months
Risk of adverse immune
response
AxoGuardTM
(from Cook Biotech)
Porcine small intestinal
submucosa (SIS) 3 months
Risk of adverse immune
response;
Risk of infectious disease
transmission
Neurotube®
(from Synovis® Micro) PGA 3 months
Rapid loss of mechanical
properties; acid degradation
products
Neurolac®
(Polyganics B.V.)
Poly(DL-lactide-ε-
caprolactone) 16 months
Rigidity and inflexibility;
foreign body reactions;
polymer fragments
Table 2. Clinically-approved nerve guidance conduits (adapt with permission from [60, 81-83]).
3.5. Next generation of nerve guidance conduits in tandem with stem cell delivery
Stem cells have been used with nerve conduits or 3D scaffolds to obtain the maximum efficient
therapeutic effects of nerve repair. Stem cells-loaded nerve conduits and 3D scaffolds have
much higher potential for nerve repair compared with nerve conduits or 3D scaffolds alone.
For example, Park et al. cultured NSCs in PGA scaffolds for 4 days before transplantation. And
then NSC-PGA complexes were transplanted into the infarction cavity of the brains in the
mouse model of hypoxia ischemic injury by glass micropipettes. The results showed that PGA
provides a good support the survival and neuronal differentiation of transplanted NSCs.
Transplanted NSCs differentiates into neurons in the infarct area. Antegrade and retrograde
tract tracing showed that transplanted projects the axons to internal and external capsule and
the contralateral hemisphere through corpus callosum. Animal behavioral function has not
been tested in this report [84]. Liu et al. transplanted ADSCs-loaded biodegradable GGT nerve
conduits containing genipin crosslinked gelatin annexed with tricalcium phosphate (TCP)
ceramic particles into 10 mm gap in the sciatic nerve after injury. They found that ADSCs could
differentiate into neuron-like cells in the GGT nerve conduits and ADSCs-loaded biodegrad‐
able GGT nerve conduits significantly increased sciatic function index and functional recovery
[85]. Furthermore, BDNF or GDNF-transfected NSCs-seeded PLA microporous nerve conduits
were transplanted into sciatic nerve gap after injury. The conduits seeded with GDNF-and
BDNF-transfected NSCs significantly increased the degree of myelination and the size of
regenerated tissue compared with those seeded with the nontransfected NSCs. The greatest
number of blood vessels was found in the animals transplanted with GDNF-transfected NSCs-
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seeded PLA microporous nerve conduits. The functional recovery was significantly improved
for BDNF or GDNF-transfected NSCs-seeded conduits assessed by the functional gait and
electrophysiology [86].
PCL conduits filled with bone marrow-derived MSCs were tested for repair of transected
sciatic nerves in mice [87]. Use of the MSCs grafted conduits was shown to significantly
improve the survival of sensory neurons and motor function, and restore gastrocnemius
muscle function in mice. In a separate study, MSCs were loaded to silk fibroin-based conduits
that were filled with oriented silk fibroin filaments, which were tested for bridging a 10 mm-
long gap in rat sciatic nerve [88]. At the early weeks after nerve grafting, the grafted MSCs
were shown to enhance the gene expression of several growth factors, such as BDNF, bFGF,
and ciliary neurotrophic factor, and S100, a marker of Schwann cells. These were arguably
responsible for accelerated axonal elongation at 4 weeks, and an improved outcome in sciatic
nerve regeneration and functional recovery at weeks 12 in the groups treated with MSC-
grafted conduits, when compared to those treated with acellular conduits. The nerve regen‐
eration efficacy of the MSC-grafted conduits was shown to approach that of autologous nerve
grafts.
4. Nerve conduits in clinical applications
In the past decades, autogenous and polymer-based nerve conduits have been used for nerve
repair in clinic. Both of them have showed positive clinical outcomes in the patients.
4.1. Biological autogenous nerve conduits in clinical applications
Previous clinical studies show that autogenous vein conduits are able to repair nerve injury in
patients. A retrospective clinical study evaluated 22 digital nerve repairs in the finger using
autogenous vein conduits, and reported that two-point discrimination for 11 acute digital
nerve repairs with vein grafts and poor results for delayed digital nerve repair [89]. In 1990,
Chiu and Strauch compared autogenous vein grafts with conventional nerve graft in 22
patients. They demonstrated that autogenous vein grafts were as efficient as conventional
nerve grafts to bridge a small nerve gap (≤3 cm). But this study did show how long these
patients were operated after nerve injury [90]. Similar clinical study was performed by Laveaux
et al., and reported that vein grafts is less efficient than nerve grafts in delayed nerve repair
and vein grafts produce similar good results in emergency cases [91]. A long-term sensory
evaluation of nerve repair was performed by Lee and Shieh, and reported that vein conduit
grafts could produce excellent sensory recovery [92]. In 2001, Pogrel and Maghen used
autogenous vein grafts to repair continuity defects, ranged from 2 to 14 mm, of the inferior
alveolar nerves (n=6) and lingual nerves (n=10). All the patients received grafts between 4 and
10 months after injury. They found that vein grafts can form a physiological conduit for nerve
regeneration and are more successful with short gaps [93]. More recent interesting study
implanted male vein grafts to femoral nerve injury of female rats and found that male vein
cells could integrate into female injured nerve and participate in remyelination and nerve
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regeneration [94]. In 2012, Liard et al. evaluated that adult neural stem cells-loaded autogenous
vein grafts to reconstruct nerve gaps in pig model and demonstrated that neural stem cells
transplantation increased 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNPase) expression
and promoted functional recovery of stimulodetection [95].
Autogenous muscle grafts are another option to provide a scaffold for the nerve fiber to grow.
In 1988, Norris et al. used frozen and thawed to denature skeletal muscle and transplanted
skeletal muscle to injured digital nerves in 8 patients. 7 out of 8 showed an excellent level of
recovery, MRC sensory clinical score S3+[96]. In 2008, Pereira et al. treated 38 patients with
leprosy by skeletal muscle autografts ranging between 2.5 cm and 14 cm length. The clinical
results showed that sensory recovery was noted in 89% patients and 80 % of ulcers caused by
posterior tibial nerve damage were healed [97]. Furthermore, to increase clinical effects, the
vein conduits filled with muscle are also used to bridge peripheral nerve gaps. The basic idea
is that vein could provide regeneration guidance and muscle serves supporter to avoid vein
collapse. In 1993, Brunelli et al. reported that vein plus muscle grafts could have similar
functional recovery to those found in traditional nerve grafts. More interestingly, axon number
in vein plus muscle grafts group is significantly higher than that of traditional nerve grafts
group [98]. In 2000, similar work was done by Battiston et al. 21 patients suffered nerve defects
of 5-60 mm were treated with vein filled with skeletal muscle. 85% of patients showed good
clinical results [99].
Although vein and muscle grafts are more available than nerve grafts, isolating vein and
muscle grafts also need second operation. To overcome this critical clinical problem, scientists
have developed different synthetic polymer-based nerve conduits for nerve repair.
4.2. Synthetic polymer-based nerve conduits in clinical applications
In 1998, Sanda Stanec and Zdenko Stanec used non-absorable polytetrafluoroethylene (ePTFE)
tube to reconstruct nerve defects between 1.5 to 6 cm length, and demonstrated that 78.6%
patients suffered 1.5 to 4 cm length nerve defects had functional motor and sensory recovery,
but only 13.3% patients suffered 4.1 to 6 cm length defects had similar recovery [100]. Due to
non-absorable nerve conduits need secondary surgery to remove them, most of synthetic nerve
conduits are made of biodegradable materials. In 2009, Rosson et al. evaluated 6 patients with
short-gap motor nerve injuries treated with bioabsorbable conduit, the NeurotubeTM, and
observed that all patients had some return of motor function. It demonstrated that motor
nerves with short-gap injuries could regenerate cross this conduit [101]. In 2011, Rinker and
Liau compared the clinical output of woven polyglycolic acid and autogenous vein conduits
for reconstruction of digital nerve gaps and reported that sensory recovery after digital nerve
reconstruction with autogenous vein conduit was similar to that using polyglycolic acid
conduit and similar cost profile and less postoperative complications were observed in both
of them [102]. Taras et al. reconstructed 22 isolated digital nerve lacerations in 19 patients with
a bioabsorable collagen conduit, and showed that 13 out of 22 achieved excellent results, 3 of
22 obtained good results, and there were no poor results [103]. A retrospective study of 10
cases was performed by Thomsen et al. in 2010. All patients were operated on for painful
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neuroma and underwent repair with collagen conduits (Revolnerv®, Orthomed). Fifty percent
patients had excellent or good results at static two-point discrimination testing [104].
Although nerve conduits are commercially available, their clinical application is far satisfied.
Limitations of nerve conduits in peripheral nerve repairs were reported by Moore et al, in 2009.
In this 4 cases report, 3 patients were treated with type I collagen nerve conduit (NeuraGen,
Integra NeuroSciences) and 1 patient was treated with polyglycolic acid nerve conduit (GEM
Neurotube, Synovis, Birmingham, AL, USA). There were no clinical effects in these patients.
Side effects were reported by some patients [105]. In 2010, Wangensteen and Kalliainen
reviewed 96 patients’ clinical data, who received type I collagen nerve conduit (NeuraGen,
Integra NeuroSciences) for nerve repair. Only 35-45% patients had sensory recovery [106].
5. Perspectives
Recent progress of biodegradable materials and stem cells provides more options for nerve
regeneration. Neural tissue engineering is a new thing but has been widely used for nerve
regeneration in basic research and clinical application. Although the research of peripheral
nerve repair has started many years ago, functional recovery is still unsatisfied. The functional
recovery largely depends on nerve gap, the location of injured nerve, patients’ age and
methods of treatment chosen. From the literatures, there are limited choices for nerve regen‐
eration: (1) For tiny nerve gap, microsurgery joining the distal and proximal stumps of the
damaged nerves should be first choice; (2) For small nerve gap (≤2-3 cm), autogenous nerve
or vein grafts and acellular nerve conduits can be used for nerve repair; (3) For larger nerve
gap (≥3 cm), just nerve conduits are not enough to support nerve regeneration. The studies of
animal trials showed that combination of nerve conduits with supporting cells could be best
choice to obtain maximum extent functional recovery. However, most popular animal model
for studying peripheral nerve regeneration is rat sciatic nerve injury model. Rat is a small
animal compared with human. It is impossible to expect that the similar functional recovery
would be obtained in the peripheral nerve injury patients with similar treatment done in rat
animal model. More works need to be done with large animals, such as monkey, to optimize
the approaches. Furthermore, personal medicine for cell therapy needs patients-derived cells.
Experience with induced pluripotent stem cells, induced neural stem cells, and induced
neurons make it possible to generate large quantity of patients-derived cells for clinical
application. Practically, multiple-disciplinary approaches should be combined together to
generate optimal clinical recovery for patients with peripheral nerve injury.
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